Sep 12, 2023 / 03:30PM GMT
Terence C. Flynn - Morgan Stanley, Research Division - Equity Analyst
Thanks so much for joining us, everybody. Really pleased to be here hosting Gilead. Before we get started, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley, and we're very pleased to have Dan O'Day with us. Dan is Chairman and CEO; and Andy Dickinson, who is the company's CFO. But thank you both for taking time out of your day to join us today.
Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO
Pleasure.
Questions and Answers:
Terence C. Flynn - Morgan Stanley, Research Division - Equity AnalystI thought maybe we'd start off high level. Obviously, diversification has been a key part of the Gilead story and